BACKGROUND AND PURPOSE: In the SELECT study, treatment with daclizumab high-yield process (DAC HYP) versus placebo reduced the frequency of gadolinium-enhancing (Gd(+) ) lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The objective of this post hoc analysis of SELECT was to evaluate the effect of DAC HYP on the evolution of new Gd(+) lesions to T1 hypointense lesions (T1 black holes). METHODS: SELECT was a randomized double-blind study of subcutaneous DAC HYP 150 or 300 mg or placebo every 4 weeks. Magnetic resonance imaging (MRI) scans were performed at baseline and weeks 24, 36 and 52 in all patients and monthly between weeks 4 and 20 in a subset of patients. MRI scans were evaluated for new Gd(+) lesions that evolved to T1 black holes at week 52. Data for the DAC HYP groups were pooled for analysis. RESULTS: Daclizumab high-yield process reduced the number of new Gd(+) lesions present at week 24 (P = 0.005) or between weeks 4 and 20 (P = 0.014) that evolved into T1 black holes at week 52 versus placebo. DAC HYP treatment also reduced the percentage of patients with Gd(+) lesions evolving to T1 black holes versus placebo. CONCLUSIONS: Treatment with DAC HYP reduced the evolution of Gd(+) lesions to T1 black holes versus placebo, suggesting that inflammatory lesions that evolved during DAC HYP treatment are less destructive than those evolving during placebo treatment.

Biogen Cambridge MA USA

Blizard Institute Barts and the London School of Medicine and Dentistry Queen Mary University of London London UK

Department of Neurology 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Department of Neurology and Medical Image Analysis Center MIAC University Hospital Basel Basel Switzerland

Department of Neurology Medical University of Lodz Lodz Poland

Department of Neurology Rush University Medical Center Chicago IL USA

Department of Neurology St Josef Hospital Ruhr University Bochum Bochum Germany

Department of Neurology University of Colorado School of Medicine Aurora CO USA

DKD Helios Klinik Wiesbaden Wiesbaden Germany

Citace poskytuje Crossref.org

Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis